Clinico-Genomics for Improved Ovarian Cancer Treatment

改善卵巢癌治疗的临床基因组学

• 批准号: 7498462
• 负责人: JENNIFER L. CLARKE
• 金额: $ 13.4万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-08-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7498462
• 关键词: Adjuvant; Adjuvant Therapy; Area; Biological Response Modifier Therapy; Breast; Cancer Biology; Characteristics; Clinical; Collaborations; Communities; Complement; Cytotoxic Chemotherapy; DNA Damage; Data; Detection; Development; Disease; Doctor of Medicine; Doctor of Philosophy; Duke Comprehensive Cancer Center; Education; Environment; Epidemiologic Studies; Epidemiologist; Epidemiology; Epithelial ovarian cancer; Family Practice; Gene Expression; Gene Expression Profiling; Genes; Genetic Polymorphism; Genetic Predisposition to Disease; Genome; Genomics; Goals; Grant; Individual; Inherited; Institutes; Knowledge; Malignant neoplasm of ovary; Measures; Mentors; Mentorship; Methodology; Molecular; Molecular Epidemiology; Molecular Profiling; Nature; Oncologist; Outcome; Ovarian; Pathologic; Pathway interactions; Patients; Pattern; Platinum; Policies; Population; Positioning Attribute; Preventive; Program Development; Radioimmunotherapy; Recurrence; Relative Risks; Research; Resistance; Risk Factors; Senior Scientist; Staging; Standards of Weights and Measures; Taxane Compound; Technology; Treatment Protocols; Universities; Work; antiangiogenesis therapy; base; cancer epidemiology; cancer genomics; cancer prevention; cancer risk; cancer therapy; case control; chemotherapy; clinical application; computerized tools; design; disorder risk; gene therapy; genetic epidemiology; improved; knowledge base; molecular oncology; novel strategies; novel therapeutics; oncology; professor; programs; response; skills; statistics; taxane; therapeutic target; tool; tumor; tumorigenesis

DESCRIPTION (provided by applicant): My primary objective is the development of a knowledge base in cancer genomics and oncology that will complement my knowledge in statistics and enables me to identify and apply my statistical skills and abilities in promising areas of breast and ovarian cancer genomics through my position as Senior Scientist in the Computational and Applied Genomics Program (CAGP) in the Institute for Genome Studies and Policy (IGSP) at Duke University. My proposed program involves formal coursework in cancer biology, genetics, and epidemiology tailored to the specific loci of this grant and the context of oncogenesis. I will apply my knowledge in molecular oncology through participation in the lab of my mentor, Joe Nevins, Ph.D., Director of the Center for Genome Technology in IGSP. Andrew Berchuck, M.D., gynecological oncologist in the Duke Comprehensive Cancer Center, will serve as my co-mentor and will direct my education in the clinical application of my knowledge within the context of ovarian cancer. My education in cancer epidemiology will progress through coursework and research in genetic epidemiology under the co-mentorship of Joellen Schildkraut, Ph.D., Director of the Epidemiology Division of the Program in Cancer Prevention, Detection, and Control and Associate Professor in the Department of Community and Family Medicine in the Duke Comprehensive Cancer Center. The goals of my research plan take advantage of recent developments in the use of genome-scale measures of gene expression and advanced computational tools to identify patterns of gene expression that are associated with or predict various characteristics and outcomes in ovarian cancers. My research is designed to aid in the identification of strategies for developing new therapeutic targets for the treatment of patients with advanced-stage epithelial ovarian cancer who do not respond to platinum/taxane-based adjuvant therapy and may or may not respond to salvage chemotherapy. I believe the importance of this work lies in the fact that chemosensitivity is the major determinant of outcome for advanced stage epithelial ovarian cancer, and the ability to predict outcomes such as chemo-responsiveness will be a powerful tool in disease treatment. A cooperative goal is to determine whether distinct subsets of ovarian cancer can be better defined by simultaneous consideration of etiologic and inherited risk factors and molecular features as expressed in gene expression data. This strategy represents a new approach in seeking to delineate the molecular epidemiology of ovarian cancer and may identify gene polymorphisms which influence relative risk of disease and clinical outcome. The potential results represent a useful tool in determining the most appropriate treatment protocol for each patient. The proposed development program has been designed to provide me with a background in cancer genomics and epidemiology which will enable me to focus the interdisciplinary nature of the CAGP environment on cancer genomic research collaborations between geneticists, breast and ovarian oncologists, statisticians, and epidemiologists.

描述（由申请人提供）：我的主要目的是发展癌症基因组学和肿瘤学知识基础，这将补充我在统计学上的知识，使我能够通过我在计算和应用基因组学计划（CAGP）中在乳腺癌和卵巢癌基因组中的有前途的乳腺癌和卵巢癌基因组学领域（CAGP）在基因组研究和政策中的乳房和卵巢癌基因组学领域（duke）（IGIG）（IGIG）（IGIG）（IGIG）。我提出的计划涉及针对该赠款的特定基因座和肿瘤发生的特定基因座量身定制的癌症生物学，遗传学和流行病学的正式课程。我将通过参与IGSP基因组技术中心主任Joe Nevins博士的实验室来应用我在分子肿瘤学方面的知识。杜克大学综合癌症中心的妇科肿瘤学家的Andrew Berchuck将担任我的同事，并将指导我的教育在卵巢癌的临床上应用我的知识。我在癌症流行病学方面的教育将在Joellen Schildkraut博士的同事下进行遗传流行病学的课程和研究。 我的研究计划的目标利用了使用基因表达和高级计算工具的基因组规模测量方面的最新发展，以识别与卵巢癌中各种特征和结果相关的基因表达模式。我的研究旨在帮助鉴定开发新的治疗靶标的策略，以治疗晚期上皮卵巢癌患者，他们对基于铂/紫杉烷的辅助治疗不反应，并且可能会或可能不会对拯救化学疗法做出反应。我认为这项工作的重要性在于，化学敏感性是晚期阶段上皮卵巢癌预后的主要决定因素，并且预测诸如化学反应性等结果的能力将是疾病治疗的有力工具。一个合作的目标是确定是否可以通过同时考虑病因和遗传的危险因素和分子特征来更好地定义卵巢癌的不同子集，如基因表达数据所示。该策略是一种新的方法，试图描绘卵巢癌的分子流行病学，并可能鉴定出影响疾病相对风险和临床结果的基因多态性。潜在结果代表了确定每个患者最合适的治疗方案的有用工具。 拟议的开发计划旨在为我提供癌症基因组学和流行病学的背景，这将使我能够将CAGP环境的跨学科性质集中在遗传学家，乳腺癌和卵巢肿瘤学家，统计学家，统计学家和流行病学家之间的癌症基因组研究合作上。